JPS62212399A - モノクロ−ナル抗体 - Google Patents
モノクロ−ナル抗体Info
- Publication number
- JPS62212399A JPS62212399A JP61056358A JP5635886A JPS62212399A JP S62212399 A JPS62212399 A JP S62212399A JP 61056358 A JP61056358 A JP 61056358A JP 5635886 A JP5635886 A JP 5635886A JP S62212399 A JPS62212399 A JP S62212399A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- human
- antibody
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims abstract description 62
- 102000036639 antigens Human genes 0.000 claims abstract description 24
- 108091007433 antigens Proteins 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 13
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 8
- 210000001685 thyroid gland Anatomy 0.000 claims abstract description 7
- 210000004072 lung Anatomy 0.000 claims abstract description 6
- 210000005036 nerve Anatomy 0.000 claims abstract description 6
- 210000000813 small intestine Anatomy 0.000 claims abstract description 6
- 210000003734 kidney Anatomy 0.000 claims abstract description 5
- 210000001519 tissue Anatomy 0.000 claims description 21
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 13
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 210000003238 esophagus Anatomy 0.000 claims description 6
- 210000002429 large intestine Anatomy 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 210000000981 epithelium Anatomy 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 210000002919 epithelial cell Anatomy 0.000 claims description 3
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 206010018338 Glioma Diseases 0.000 claims 2
- 210000004408 hybridoma Anatomy 0.000 abstract description 25
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 abstract description 6
- 206010003445 Ascites Diseases 0.000 abstract description 5
- 238000003113 dilution method Methods 0.000 abstract description 3
- 230000007910 cell fusion Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 230000002685 pulmonary effect Effects 0.000 abstract 3
- 210000000683 abdominal cavity Anatomy 0.000 abstract 1
- 210000004100 adrenal gland Anatomy 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 230000003393 splenic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 20
- 230000009257 reactivity Effects 0.000 description 19
- 239000000427 antigen Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 13
- 239000002609 medium Substances 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 241001494479 Pecora Species 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000011725 BALB/c mouse Methods 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000003200 peritoneal cavity Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 229960003896 aminopterin Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000007640 basal medium Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000003677 hemocyte Anatomy 0.000 description 2
- 229940000351 hemocyte Drugs 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010073073 Hepatobiliary cancer Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- 101710113246 Pectinesterase 3 Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000004412 neuroendocrine cell Anatomy 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61056358A JPS62212399A (ja) | 1986-03-14 | 1986-03-14 | モノクロ−ナル抗体 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61056358A JPS62212399A (ja) | 1986-03-14 | 1986-03-14 | モノクロ−ナル抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1243599A Division JPH02174691A (ja) | 1989-09-21 | 1989-09-21 | モノクローナル抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62212399A true JPS62212399A (ja) | 1987-09-18 |
| JPH0217160B2 JPH0217160B2 (enExample) | 1990-04-19 |
Family
ID=13025019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61056358A Granted JPS62212399A (ja) | 1986-03-14 | 1986-03-14 | モノクロ−ナル抗体 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62212399A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0323802A3 (en) * | 1987-12-24 | 1989-07-26 | Sandoz Ag | Monoclonal antibodies against, and cell surface antigen of, lung carcinoma |
-
1986
- 1986-03-14 JP JP61056358A patent/JPS62212399A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0323802A3 (en) * | 1987-12-24 | 1989-07-26 | Sandoz Ag | Monoclonal antibodies against, and cell surface antigen of, lung carcinoma |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0217160B2 (enExample) | 1990-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4683200A (en) | Monoclonal antibody to human cancer antigen and method for producing same | |
| KR900003923B1 (ko) | 인체 암종양과 관련된 항원에 대한 단일클론성 항체 | |
| IE870487L (en) | Lung carcinoma antigen and antibody | |
| US4800155A (en) | Human monoclonal antibody to lung carcinoma and hybridoma producing the same | |
| CN108997499A (zh) | 一种抗人pd-l1抗体及其应用 | |
| CN108997500A (zh) | 一种抗人pd-l1抗体及其应用 | |
| AU598447B2 (en) | Monoclonal antibody to human adenocarcinoma cells, and its preparation and use | |
| JPS62212399A (ja) | モノクロ−ナル抗体 | |
| EP0428485A1 (en) | Novel antiidiotypic monoclonal antibodies | |
| JPS6143200A (ja) | モノクロ−ナル抗体 | |
| CN118307677B (zh) | 一种针对间皮素的单克隆抗体及应用 | |
| JPS60199830A (ja) | モノクロ−ナル抗体 | |
| CA1217737A (en) | Process for obtaining monoclonal antibodies directed against tumour antigens and pharmaceutical compositions containing them | |
| JPH02174691A (ja) | モノクローナル抗体 | |
| JPS61236798A (ja) | モノクロ−ナル抗体 | |
| JPS60178826A (ja) | モノクロ−ナル抗体，その製法及び抗原 | |
| JPH02238893A (ja) | 甲状腺癌特異抗原に対するモノクローナル抗体 | |
| JP2007106716A (ja) | Ｉｓｇ１５タンパク質と特異的に反応するモノクローナル抗体及びそれを産生するハイブリドーマ並びに癌およびウイルス感染の検出方法 | |
| JPS60243026A (ja) | モノクロ−ナル抗体 | |
| US4990454A (en) | YH206 cell line and monoclonal antibody produced by it | |
| JPS60204727A (ja) | 抗ヒトｖ型コラ−ゲン抗体 | |
| Fujii et al. | Characterization of a murine monoclonal antibody, 5D-4, reacting with pancreatic cancers and islets of Langerhans | |
| JPS61289880A (ja) | 新規ハイブリド−マ，その製造法および用途 | |
| WO1990002761A1 (fr) | Anticorps monoclonal humain et procede de preparation | |
| SU1273115A1 (ru) | Штамм культивируемых гибридных клеток А6/1-Д-продуцент моноклональных антител к полисахариду стрептококка группы А,перекрестно-реагирующих с эпителием |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |